Clinical Trials Logo

Clinical Trial Summary

Data from the wistar institute indicated that this anti-body labeled with iodine-125 would localized in the tumor cells of high grade gliomas of the brain. the project combines surgery, radiation therapy, chemotherapy with the labeled antibody in a prospective phase II trial in this disease entity.


Clinical Trial Description

This is an open-label Phase II study of postoperative radiation therapy followed by Iodine-125 radiolabeled anti-epidermal-growth-factor-receptor monoclonal antibody (125I-MAB 425) derived from cell cultures for high grade malignant gliomas. Each subject will receive postoperative radiation therapy followed by 6.4 mg of 50 mCi labeled 125I-MAB 425 by injection. This dosing regimen will be given three times generally within a two-week period (days one, eight and 15 of therapy) for a total dose of 19.2 mg of 150 mCi labeled 125I-MAB 425 for each course of therapy. The main objective of this study is to determine if the addition of 125I-MAB 425 to postoperative radiotherapy, with or without change, prolongs absolute survival compared to historical control (postoperative radiation therapy alone) in subjects with histologically proven high grade gliomas. The primary efficacy variable is absolute survival and the secondary target variable will be time to progression of the tumor. Multiple courses will be considered based on the subject`s clinical status. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00589706
Study type Interventional
Source Drexel University
Contact
Status Completed
Phase Phase 2
Start date January 1985
Completion date December 2012

See also
  Status Clinical Trial Phase
Recruiting NCT03952598 - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy N/A
Not yet recruiting NCT01445691 - More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery Phase 2
Terminated NCT01251913 - A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
Withdrawn NCT01961934 - C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression Phase 2/Phase 3
Active, not recruiting NCT03557359 - Nivolumab for Recurrent or Progressive IDH Mutant Gliomas Phase 2
Recruiting NCT01655927 - Efficacy of Tranexamic Acid in Brain Tumor Resections Phase 3
Completed NCT01225003 - Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas N/A
Completed NCT01144247 - Cellular Immunotherapy Study for Brain Cancer Phase 1
Completed NCT00967577 - 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors Phase 1
Terminated NCT01517776 - Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents Phase 2
Completed NCT00832598 - [18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors N/A
Completed NCT03154996 - Chronic Convection Enhanced Delivery of Topotecan Phase 1
Withdrawn NCT05054400 - Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR Early Phase 1
Recruiting NCT03091270 - ZOOMit-fMRI Identifies Motor Functional Cortex
Completed NCT00200161 - Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma Phase 2
Terminated NCT02332889 - Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs Phase 1/Phase 2
Recruiting NCT05804227 - Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults Early Phase 1